Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy

December 29, 2010 By Bio-Medicine.Org

SEATTLE, Dec. 29, 2010 /PRNewswire-FirstCall/ — Omeros
Corporation (Nasdaq:
OMER
), a biopharmaceutical company committed to discovering,
developing and commercializing products focused on inflammation and
disorders of the central nervous system, today announced results
from the Phase 1/2 clinical trial of OMS201, the Company’s
urological PharmacoSurgery™ product candidate. OMS201 is a
proprietary combination of an anti-inflammatory agent and a smooth
muscle relaxant, each with well-known safety and pharmacologic
profiles.

Based on the successfully completed Phase 1 trial of a lower
concentration of OMS201, this Phase 1/2 study was designed to
evaluate the safety and systemic absorption of two sequentially
higher concentrations of OMS201 added to standard irrigation
solution and delivered to patients undergoing ureteroscopy for
removal of ureteral or renal stones. This multicenter,
double-blind, placebo-controlled study also explored potential
efficacy endpoints but was not powered to assess efficacy. Based on
an interim analysis of the pharmacokinetic data, which demonstrated
low maximal systemic absorption of the active ingredients, trial
enrollment was truncated from the originally planned 36 patients to
a total of 24 patients.

OMS201 was safe and well tolerated in this study. The incidence
of adverse events was similar in the two OMS201-concentration arms
and the group receiving vehicle. No adverse events were considered
treatment-related by investigators. There were no deaths or
discontinuations for adverse events. Only one serious adverse event
was reported, which occurred in a vehicle-treated patient.

“We are pleased with the results of this trial, which
demonstrated an absence of side-effects even at a concentration of
OMS201 ten times higher than that examined in our earlier Phase 1
clinical study,” said Gregory A. Demopulos, M.D., chairman
and

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech